At a glance
Summary
Johnson & Johnson added 3.8% in the week to 21 August, keeping its 73-week active Trend backdrop intact and leaving the stock in the top 6% of its 52-week range. The read is constructive but not one-sided: price strength, positive Market Dynamics and Relative Strength are offset by 0.9x volume, a 56.6% premium to Sharemaestro Fair Value and signs that pressure and relative performance have eased over four weeks.
- JNJ closed at 270.2 USD, up 3.8% for the week and 19.9% over 12 weeks, with the latest close 2.3% below the 276.5 USD 52-week high.
- The weekly Trend backdrop remains Active, with price 11.8% above the 241.6 USD Trend Line and active trend coverage across all 52 weeks.
- Volume was 33.7M shares, equal to 0.9x the 13-week average of 38.3M and 0.8x the 52-week average of 40.0M, leaving participation only moderate.
- Healthcare was broadly positive, with the sector averaging 4.0% for the week; JNJ was slightly behind that, but ahead of its Drug Manufacturers - General industry average of 3.1%.
- The valuation gap is substantial, with the stock 56.6% above Sharemaestro Fair Value of 172.6 USD, raising the importance of continued trend and volume confirmation.
Company analysis
The move in context
Price action holds near the high
Johnson & Johnson ended the latest completed week at 270.2 USD, a 3.8% gain that pushed the stock to 94.1% of its 52-week range. The close sits just 2.3% below the 276.5 USD high and well above the 170.4 USD low, preserving a constructive weekly profile after a 19.9% 12-week advance and a 54.5% one-year return.
The Trend Signal remains Active, supported by a 73-week active streak and price standing 11.8% above the 241.6 USD weekly Trend Line. That cushion is meaningful, but it also makes the next pullback test more important: a stock this close to its high can either consolidate healthily above trend or show exhaustion if buyers stop responding near the upper end of the range.
Healthcare breadth supports the move, though peers are mixed
The wider US Healthcare group was firm, averaging a 4.0% weekly return, with 61.0% of stocks showing active weekly trend signals, 75.0% positive Market Dynamics and 56.0% positive Relative Strength. JNJ’s 3.8% week was a slight lag versus the sector, but its 19.9% 12-week gain was ahead of the sector’s 13.9% average.
Within US Drug Manufacturers - General, the stock compared better on the week and over the quarter. The industry averaged 3.1% for the week, 2.4% over four weeks and 5.9% over 12 weeks, while JNJ posted 3.8%, 2.6% and 19.9% across the same periods. Large-cap peers such as Merck, Amgen, Gilead and Bristol-Myers also showed positive weekly momentum, so JNJ is participating in a broader pharma recovery rather than moving alone.
Momentum is positive, but urgency has eased
Sharemaestro’s setup signature is a Balanced read with a composite score of 65. Market Dynamics remain positive at 0.57 and Relative Strength is positive at 11.14, but both have softened over the recent four-week window, with activity pressure down 10.5% and relative performance down 21.8%. That mix argues for strength with a moderation warning, not a clean acceleration signal.
The signal board reflects that balance. The Trend backdrop is Active and price remains comfortably above trend, but activity pressure shows no fresh buy signal and volume is neutral. The one-week and 12-week returns are positive, yet the four-week gain of 2.6% shows that the advance has become less forceful after the stronger quarter move.
Volume and valuation are the main tests from here
The latest rally came on 33.7M shares, below the 13-week average of 38.3M and the 52-week average of 40.0M. That does not invalidate the price action, but it leaves confirmation incomplete, especially when the stock is already close to a 52-week high. The strongest recent participation remains the 54.9M-share week of 26 June, when JNJ gained 11.5%.
Risk is no longer negligible for a defensive healthcare bellwether. Thirteen-week volatility is 4.2%, above the 52-week baseline of 3.1%, and the stock trades 56.6% above Sharemaestro Fair Value of 172.6 USD. The next watch points are whether JNJ can challenge 276.5 USD on heavier participation, whether activity pressure stabilises, and whether the 241.6 USD Trend Line continues to define the weekly regime if the stock pulls back.
Peer comparison
How the wider group is behaving
Breadth shows how much of the sector or industry is participating. A company move is more convincing when its peers are improving too.
US Healthcare
100 tracked companiesAbove Trend Line61.0%
Positive Relative Strength56.0%
US Drug Manufacturers - General
20 tracked companiesAbove Trend Line55.0%
Positive Relative Strength55.0%
Balanced view
What supports the case, and what could weaken it
What is working
- The trend backdrop is active with a 73-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
- Activity pressure is constructive, supporting the smart-money activity read.
What needs caution
- 4 reversal markers appear in the recent smart-money tape.
- Recent volatility is running well above the one-year baseline.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/johnson-johnson-near-high-volume-confirmation/.
Follow new Sharemaestro research through the RSS feed or JSON feed.